Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
Hematologic NeoplasmsProstatic Neoplasms
Interventions
DRUG

APR-246

Intravenous infusion. Dose escalating. Dosing will be conducted with three patients at each dose level.

Trial Locations (6)

41345

Section of Haematology and Coagulation, Sahlgrenska University Hospital, Gothenburg

70185

Department of Hematology, University Hospital, Örebro

Urology clinic, University Hospital, Örebro

75185

Clinical Research and Development Unit, Department of Oncology, Akademiska Hospital, Uppsala

Department of Haematology, Akademiska Hospital, Uppsala

SE 141 86

Hematology Centre, M54, Karolinska Institute, Karolinska University Hospital, Huddinge, Stockholm

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Aprea Therapeutics

INDUSTRY